The government of the Democratic Republic of the Congo has begun experimental trials of two treatments for Ebola disease caused by the Bundibugyo virus with support from the World Health Organization, Bloomberg reported on July 6. Treatments tested are U.S. pharmaceutical company Mapp Biopharmaceutical's monoclonal antibody cocktail MBP134 and its U.S. counterpart Gilead Sciences' antiviral remdesivir.
SUBSCRIBERS ONLY
Expert analysis when it matters most.
Get access to RANE's decision-grade geopolitical intelligence.